Zeaxanthin dipalmitate alleviates hepatic injury induced by superimposed chronic hepatitis B and non-alcoholic steatohepatitis in non-obese mice

J Asian Nat Prod Res. 2017 Sep;19(9):910-923. doi: 10.1080/10286020.2017.1349759.

Abstract

A hepatitis B virus (HBV) transgenic mice model was used to establish the fatty liver superimposed model by feeding the methionine choline-deficient (MCD) diet for 8 weeks, with or without the gavage of 2 mg/kg zeaxanthin dipalmitate (ZD) three times per week. Both wild-type and HBV transgenic mice, with MCD diet, gained typical non-obese non-alcoholic steatohepatitis (NASH) and HBV symptoms. Coadministration with ZD exhibited evident therapeutic effects through alleviating those pathological events. Moreover, long-term vehicle-ZD treatment was found to be safe. Thus, ZD is a promising and safe hepato-protective agent against hepatic injury induced by superimposed HBV and NASH in non-obese mice.

Keywords: HBV transgenic mice; Non-alcoholic steatohepatitis; Zeaxanthin dipalmitate; chronic hepatitis B; protective effect.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Hepatitis B virus
  • Hepatitis B, Chronic / drug therapy*
  • Liver / drug effects
  • Lycium / chemistry
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Molecular Structure
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Palmitates / chemistry
  • Palmitates / pharmacology*
  • Xanthophylls / chemistry
  • Xanthophylls / pharmacology*

Substances

  • Palmitates
  • Xanthophylls
  • zeaxanthin dipalmitate